Paclitaxel induced chronic fibrosing interstitial pneumonitis: A case report and review of the literature

Pulmonary toxicity is rarely associated with paclitaxel chemotherapy and its mechanism is not well known. This report describes one patient with pancreatic adenocarcinoma, metastatic neuroendocrine low-grade pancreatic tumor, and a concomitant stage I non-small cell lung cancer (NSCLC), who also developed life-threatening paclitaxel-induced chronic fibrosing interstitial pneumonitis. Giving the gravity of the condition and the not-wellestablished treatment, physicians should be aware of the possibility of chronic fibrosing interstitial lung disease during the course of paclitaxel containing regimens in patients who present with respiratory symptoms.